Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00000568 |
In the Lung Health Study I, to determine the effects of Special Care, compared to Usual Care, on rate of decline in pulmonary function in a group of cigarette smokers identified as having mild abnormalities in pulmonary function.
In the Lung Health Study III, to determine the long-term effects of smoking cessation and continued smoking, on cardiopulmonary morbidity, mortality, and the rate of decline in the one second forced expiratory volume (FEV1) in men and women with early chronic obstructive lung disease who have been followed prospectively for 12 to 15 years.
Condition | Intervention | Phase |
---|---|---|
Lung Diseases Lung Diseases, Obstructive Chronic Obstructive Pulmonary Disease |
Behavioral: smoking cessation Drug: ipratropium |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control |
Study Start Date: | September 1984 |
Estimated Study Completion Date: | January 2005 |
Ages Eligible for Study: | 35 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Men and women who were cigarette smokers and between the ages of 35 and 60.
Study ID Numbers: | 206 |
Study First Received: | October 27, 1999 |
Last Updated: | August 17, 2005 |
ClinicalTrials.gov Identifier: | NCT00000568 |
Health Authority: | United States: Federal Government |
Lung Diseases, Obstructive Ipratropium Respiratory Tract Diseases Lung Diseases Pulmonary Disease, Chronic Obstructive |
Respiratory System Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Cholinergic Antagonists Autonomic Agents Therapeutic Uses |
Physiological Effects of Drugs Anti-Asthmatic Agents Peripheral Nervous System Agents Cholinergic Agents Bronchodilator Agents Pharmacologic Actions |